Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorNeves, Renata
dc.contributor.authorDe Dios Perez, Blanca
dc.contributor.authorPanek, Rafal
dc.contributor.authorJagani, Sumit
dc.contributor.authorWilne, Sophie
dc.contributor.authorBHATT, JAYESH MAHENDRA
dc.contributor.authorSoler-Palacin, Pere
dc.date.accessioned2023-09-13T11:42:21Z
dc.date.available2023-09-13T11:42:21Z
dc.date.issued2023-07
dc.identifier.citationNeves R, De Dios Perez B, Panek R, Jagani S, Wilne S, Bhatt JM, et al. Development of cancer surveillance guidelines in ataxia telangiectasia: A Delphi-based consensus survey of international experts. Cancer Med. 2023 Jul;12(13):14663–73.
dc.identifier.issn2045-7634
dc.identifier.urihttps://hdl.handle.net/11351/10272
dc.descriptionAtaxia telangiectasia; Cancer predisposition; International survey
dc.description.abstractBackground/Objectives Ataxia telangiectasia (A-T) is a multiorgan disorder with increased vulnerability to cancer. Despite this increased cancer risk, there are no widely accepted guidelines for cancer surveillance in people affected by A-T. We aimed to understand the current international practice regarding cancer surveillance in A-T and agreed-upon approaches to develop cancer surveillance in A-T. Design/Methods We used a consensus development method, the e-Delphi technique, comprising three rounds. Round 1 consisted of a Delphi questionnaire and a survey that collected the details of respondents' professional background, experience, and current practice of cancer surveillance in A-T. Rounds 2 and 3 were designed based on previous rounds and modified according to the comments made by the panellists. The pre-specified consensus threshold was ≥75% agreement. Results Thirty-five expert panellists from 13 countries completed the study. The survey indicated that the current practice of cancer surveillance varies widely between experts and centres'. Consensus was reached that evidence-based guidelines are needed for cancer surveillance in people with A-T, with separate recommendations for adults and children. Statements relating to the tests that should be included, the age for starting and stopping cancer surveillance and the optimal surveillance interval were also agreed upon, although in some areas, the consensus was that further research is needed. Conclusion The international expert consensus statement confirms the need for evidence-based cancer surveillance guidelines in A-T, highlights key features that the guidelines should include, and identifies areas of uncertainty in the expert community. This elucidates current knowledge gaps and will inform the design of future clinical trials.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesCancer Medicine;12(13)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCàncer - Propensió
dc.subjectDecisió de grup
dc.subjectAtàxia
dc.subject.meshAtaxia Telangiectasia
dc.subject.meshNeoplasms
dc.subject.meshDelphi Technique
dc.titleDevelopment of cancer surveillance guidelines in ataxia telangiectasia: A Delphi-based consensus survey of international experts
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/cam4.6075
dc.subject.decsataxia telangiectasia
dc.subject.decsneoplasias
dc.subject.decstécnica Delfos
dc.relation.publishversionhttps://doi.org/10.1002/cam4.6075
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Neves R] Radiological Sciences, School of Medicine, University of Nottingham, Nottingham, UK. Department of Radiology, Nottingham University Hospitals NHS Trust, Nottingham, UK. [De Dios Perez B] Centre for Rehabilitation and Ageing Research, School of Medicine, University of Nottingham, Nottingham, UK. [Panek R] Medical Physics & Clinical Engineering, Nottingham University Hospitals NHS Trust, Nottingham, UK. [Jagani S] Department of Radiology, Nottingham University Hospitals NHS Trust, Nottingham, UK. [Wilne S] Department of Paediatric Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK. [Bhatt JM] Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK. UK National Paediatric Ataxia Telangiectasia Clinic, Nottingham University Hospitals NHS Trust, Nottingham, UK. [Soler-Palacin P] Unitat de Patologia Infecciosa i Immunodeficiències de Pediatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid37264737
dc.identifier.wos001000690000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record